Advertisement

European Journal of Dermatology

, Volume 28, Issue 5, pp 711–713 | Cite as

Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?

  • Aikaterini PatsatsiEmail author
  • Aikaterini Kyriakou
  • Parthena Meltzanidou
  • Anastasia Trigoni
  • Foteini Lamprou
  • Miltiadis Kokolios
  • Anastasia Giannakou
Article
  • 2 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    MendonÇa FM, Martín–Gutierrez FJ, Ríos–Martín JJ, Camacho–Martinez F. Three cases of bullous pemphigoid associated with dipeptidyl peptidase–4 inhibitors–one due to linagliptin. Dermatology 2016; 232: 249–53.CrossRefGoogle Scholar
  2. 2.
    Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug–induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase–IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249–53.CrossRefGoogle Scholar
  3. 3.
    Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase–4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 2011; 34: e133.CrossRefGoogle Scholar
  4. 4.
    Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep 2014; 8: 24–8.Google Scholar
  5. 5.
    García M, Aranburu MA, Palacios–Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase–IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther 2016; 41: 368–70.CrossRefGoogle Scholar
  6. 6.
    Haber R, Fayad AM, Stephan F, Obeid G, Tomb R. Bullous pemphigoid associated with linagliptin treatment. JAMA Dermatol 2016; 152: 224–6.CrossRefGoogle Scholar
  7. 7.
    Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol 2016; 136: 2201–10.CrossRefGoogle Scholar
  8. 8.
    Fania L, Salemme A, Provini A, et al. Detection and characterization of IgG, IgE and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase–IV inhibitors. J Am Acad Dermatol 2018; 78: 592–5.CrossRefGoogle Scholar
  9. 9.
    Béné J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case–noncase study in the French Pharmacovigilance Database. Br J Dermatol 2016; 175: 296–301.CrossRefGoogle Scholar
  10. 10.
    Schaffer C, Buclin T, Jornayvaz FR, et al. Use of dipeptidylpeptidase IV inhibitors and bullous pemphigoid. Dermatology 2017; 233: 401–3.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Aikaterini Patsatsi
    • 1
    Email author
  • Aikaterini Kyriakou
    • 1
  • Parthena Meltzanidou
    • 1
  • Anastasia Trigoni
    • 1
  • Foteini Lamprou
    • 1
  • Miltiadis Kokolios
    • 1
  • Anastasia Giannakou
    • 2
  1. 1.Autoimmune Bullous Diseases Outpatient Clinic, 2nd Department of Dermatology, Aristotle University School of MedicinePapageorgiou General HospitalThessalonikiGreece
  2. 2.Laboratory of ImmunologyPapageorgiou General HospitalThessalonikiGreece

Personalised recommendations